Is V1TA34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of V1TA34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: V1TA34 (R$185.44) is trading above our estimate of fair value (R$181.05)
Significantly Below Fair Value: V1TA34 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for V1TA34?
Key metric: As V1TA34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for V1TA34. This is calculated by dividing V1TA34's market cap by their current
revenue.
What is V1TA34's PS Ratio?
PS Ratio
5.6x
Sales
US$4.80b
Market Cap
US$26.88b
V1TA34 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: V1TA34 is good value based on its Price-To-Sales Ratio (5.6x) compared to the Global Health Care REITs industry average (6.5x).
Price to Sales Ratio vs Fair Ratio
What is V1TA34's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
V1TA34 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
5.6x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate V1TA34's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.